Genetic and phenotypic variability of optic neuropathies

References

• Biousse V, Newman NJ. Hereditary optic neuropathies. Ophthalmol. Clin. North Am. 14(3), 547–568 (2001).
   PubMedGoogle Scholar
• Kjer B, Eiberg H, Kjer P, Rosenberg T. Dominant optic atrophy mapped to chromosome 3q region. II. Clinical and epidemiological aspects. Acta Ophthalmol. Scand. 74(1), 3–7 (1996).
   PubMedGoogle Scholar
• Olichon A, Guillou E, Delettre C et al. Mitochondrial dynamics and disease, OPA1. Biochim. Biophys. Acta 1763(5–6), 500–509 (2006).
   PubMed Web of Science ®Google Scholar
• Newman NJ, Biousse V. Hereditary optic neuropathies. Eye (Lond.) 18(11), 1144–1160 (2004).
   PubMed Web of Science ®Google Scholar
• Züchner S, De Jonghe P, Jordanova A et al. Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2. Ann. Neurol. 59(2), 276–281 (2006).
   PubMed Web of Science ®Google Scholar
• Züchner S, Mersiyanova IV, Muglia M et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot–Marie–Tooth neuropathy type 2A. Nat. Genet. 36(5), 449–451 (2004).
   PubMed Web of Science ®Google Scholar
• Kim HJ, Sohn KM, Shy ME et al. Mutations in PRPS1, which encodes the phosphoribosyl pyrophosphate synthetase enzyme critical for nucleotide biosynthesis, cause hereditary peripheral neuropathy with hearing loss and optic neuropathy (cmtx5). Am. J. Hum. Genet. 81(3), 552–558 (2007).
   PubMed Web of Science ®Google Scholar
• Dong J, Edelmann L, Bajwa AM, Kornreich R, Desnick RJ. Familial dysautonomia: detection of the IKBKAP IVS20(+6T –> C) and R696P mutations and frequencies among Ashkenazi Jews. Am. J. Med. Genet. 110(3), 253–257 (2002).
   PubMed Web of Science ®Google Scholar
• Koeppen AH. The hereditary ataxias. J. Neuropathol. Exp. Neurol. 57(6), 531–543 (1998).
   PubMedGoogle Scholar
• Perlman SJ, Mar S. Leukodystrophies. Adv. Exp. Med. Biol. 724, 154–171 (2012).
   PubMedGoogle Scholar
• Renaud DL. Lysosomal disorders associated with leukoencephalopathy. Semin. Neurol. 32(1), 51–54 (2012).
   PubMedGoogle Scholar
• Kousi M, Lehesjoki AE, Mole SE. Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses. Hum. Mutat. 33(1), 42–63 (2012).
   PubMed Web of Science ®Google Scholar
• Schneider SA, Bhatia KP. Syndromes of neurodegeneration with brain iron accumulation. Semin. Pediatr. Neurol. 19(2), 57–66 (2012).
   PubMedGoogle Scholar
• Hoyt CS. Autosomal dominant optic atrophy. A spectrum of disability. Ophthalmology 87(3), 245–251 (1980).
   PubMed Web of Science ®Google Scholar
• Newman NJ, Lott MT, Wallace DC. The clinical characteristics of pedigrees of Leber’s hereditary optic neuropathy with the 11778 mutation. Am. J. Ophthalmol. 111(6), 750–762 (1991).
   PubMed Web of Science ®Google Scholar
• Oostra RJ, Bolhuis PA, Wijburg FA, Zorn-Ende G, Bleeker-Wagemakers EM. Leber’s hereditary optic neuropathy: correlations between mitochondrial genotype and visual outcome. J. Med. Genet. 31(4), 280–286 (1994).
   PubMed Web of Science ®Google Scholar
• Riordan-Eva P, Sanders MD, Govan GG, Sweeney MG, Da Costa J, Harding AE. The clinical features of Leber’s hereditary optic neuropathy defined by the presence of a pathogenic mitochondrial DNA mutation. Brain 118(Pt 2), 319–337 (1995).
   PubMed Web of Science ®Google Scholar
• Votruba M, Aijaz S, Moore AT. A review of primary hereditary optic neuropathies. J. Inherit. Metab. Dis. 26(2–3), 209–227 (2003).
   PubMedGoogle Scholar
• Votruba M, Fitzke FW, Holder GE, Carter A, Bhattacharya SS, Moore AT. Clinical features in affected individuals from 21 pedigrees with dominant optic atrophy. Arch. Ophthalmol. 116(3), 351–358 (1998).
   PubMedGoogle Scholar
• Berninger TA, Jaeger W, Krastel H. Electrophysiology and colour perimetry in dominant infantile optic atrophy. Br. J. Ophthalmol. 75(1), 49–52 (1991).
   PubMedGoogle Scholar
• Holder GE, Votruba M, Carter AC, Bhattacharya SS, Fitzke FW, Moore AT. Electrophysiological findings in dominant optic atrophy (DOA) linking to the OPA1 locus on chromosome 3q 28-qter. Doc. Ophthalmol. 95(3–4), 217–228 (1998).
   PubMedGoogle Scholar
• Yu-Wai-Man P, Griffiths PG, Gorman GS et al. Multi-system neurological disease is common in patients with OPA1 mutations. Brain 133(Pt 3), 771–786 (2010).
   PubMedGoogle Scholar
• Amati-Bonneau P, Valentino ML, Reynier P et al. OPA1 mutations induce mitochondrial DNA instability and optic atrophy ‘plus’ phenotypes. Brain 131(Pt 2), 338–351 (2008).
   PubMedGoogle Scholar
• Amati-Bonneau P, Guichet A, Olichon A et al. OPA1 R445H mutation in optic atrophy associated with sensorineural deafness. Ann. Neurol. 58(6), 958–963 (2005).
   PubMed Web of Science ®Google Scholar
• Hudson G, Amati-Bonneau P, Blakely EL et al. Mutation of OPA1 causes dominant optic atrophy with external ophthalmoplegia, ataxia, deafness and multiple mitochondrial DNA deletions: a novel disorder of mtDNA maintenance. Brain 131(Pt 2), 329–337 (2008).
   PubMed Web of Science ®Google Scholar
• Alexander C, Votruba M, Pesch UE et al. OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nat. Genet. 26(2), 211–215 (2000).
   PubMed Web of Science ®Google Scholar
• Delettre C, Lenaers G, Griffoin JM et al. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat. Genet. 26(2), 207–210 (2000).
   PubMed Web of Science ®Google Scholar
• Yu-Wai-Man P, Sitarz KS, Samuels DC et al. OPA1 mutations cause cytochrome c oxidase deficiency due to loss of wild-type mtDNA molecules. Hum. Mol. Genet. 19(15), 3043–3052 (2010).
   PubMed Web of Science ®Google Scholar
• Mascialino B, Leinonen M, Meier T. Meta-analysis of the prevalence of Leber hereditary optic neuropathy mtDNA mutations in Europe. Eur. J. Ophthalmol. 22(3), 461–465 (2012).
   PubMed Web of Science ®Google Scholar
• Nikoskelainen EK, Marttila RJ, Huoponen K et al. Leber’s “plus”: neurological abnormalities in patients with Leber’s hereditary optic neuropathy. J. Neurol. Neurosurg. Psychiatr. 59(2), 160–164 (1995).
   PubMed Web of Science ®Google Scholar
• Flanigan KM, Johns DR. Association of the 11778 mitochondrial DNA mutation and demyelinating disease. Neurology 43(12), 2720–2722 (1993).
   PubMed Web of Science ®Google Scholar
• Bhatti MT, Newman NJ. A multiple sclerosis-like illness in a man harboring the mtDNA 14484 mutation. J. Neuroophthalmol. 19(1), 28–33 (1999).
   PubMedGoogle Scholar
• Palace J. Multiple sclerosis associated with Leber’s hereditary optic neuropathy. J. Neurol. Sci. 286(1–2), 24–27 (2009).
   PubMed Web of Science ®Google Scholar
• Tarnopolsky MA, Baker SK, Myint T, Maxner CE, Robitaille J, Robinson BH. Clinical variability in maternally inherited leber hereditary optic neuropathy with the G14459A mutation. Am. J. Med. Genet. A 124A(4), 372–376 (2004).
   PubMedGoogle Scholar
• Wallace DC, Singh G, Lott MT et al. Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy. Science 242(4884), 1427–1430 (1988).
   PubMed Web of Science ®Google Scholar
• Johns DR, Neufeld MJ, Park RD. An ND-6 mitochondrial DNA mutation associated with Leber hereditary optic neuropathy. Biochem. Biophys. Res. Commun. 187(3), 1551–1557 (1992).
   PubMed Web of Science ®Google Scholar
• Howell N, McCullough D, Bodis-Wollner I. Molecular genetic analysis of a sporadic case of Leber hereditary optic neuropathy. Am. J. Hum. Genet. 50(2), 443–446 (1992).
   PubMedGoogle Scholar
• Chinnery PF, Andrews RM, Turnbull DM, Howell NN. Leber hereditary optic neuropathy: does heteroplasmy influence the inheritance and expression of the G11778A mitochondrial DNA mutation? Am. J. Med. Genet. 98(3), 235–243 (2001).
   PubMed Web of Science ®Google Scholar
• Hudson G, Carelli V, Spruijt L et al. Clinical expression of Leber hereditary optic neuropathy is affected by the mitochondrial DNA-haplogroup background. Am. J. Hum. Genet. 81(2), 228–233 (2007).
   PubMed Web of Science ®Google Scholar
• Ji Y, Jia X, Li S, Xiao X, Guo X, Zhang Q. Evaluation of the X-linked modifier loci for Leber hereditary optic neuropathy with the G11778A mutation in Chinese. Mol. Vis. 16, 416–424 (2010).
   PubMed Web of Science ®Google Scholar
• Giordano C, Montopoli M, Perli E et al. Oestrogens ameliorate mitochondrial dysfunction in Leber’s hereditary optic neuropathy. Brain 134(Pt 1), 220–234 (2011).
   PubMed Web of Science ®Google Scholar
• Kirkman MA, Yu-Wai-Man P, Korsten A et al. Gene–environment interactions in Leber hereditary optic neuropathy. Brain 132(Pt 9), 2317–2326 (2009).
   PubMed Web of Science ®Google Scholar
• Klopstock T, Yu-Wai-Man P, Dimitriadis K et al. A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy. Brain 134(Pt 9), 2677–2686 (2011).
   PubMed Web of Science ®Google Scholar
• Sadun AA, Chicani CF, Ross-Cisneros FN et al. Effect of EPI-743 on the clinical course of the mitochondrial disease Leber hereditary optic neuropathy. Arch. Neurol. 69(3), 331–338 (2012).
   PubMed Web of Science ®Google Scholar
• Reynier P, Amati-Bonneau P, Verny C et al. OPA3 gene mutations responsible for autosomal dominant optic atrophy and cataract. J. Med. Genet. 41(9), e110 (2004).
   PubMed Web of Science ®Google Scholar
• Ayrignac X, Liauzun C, Lenaers G et al. OPA3-related autosomal dominant optic atrophy and cataract with ataxia and areflexia. Eur. Neurol. 68(2), 108–110 (2012).
   PubMedGoogle Scholar
• Ryu SW, Jeong HJ, Choi M, Karbowski M, Choi C. Optic atrophy 3 as a protein of the mitochondrial outer membrane induces mitochondrial fragmentation. Cell. Mol. Life Sci. 67(16), 2839–2850 (2010).
   PubMed Web of Science ®Google Scholar
• Chevrollier A, Guillet V, Loiseau D et al. Hereditary optic neuropathies share a common mitochondrial coupling defect. Ann. Neurol. 63(6), 794–798 (2008).
   PubMed Web of Science ®Google Scholar
• Hanein S, Perrault I, Roche O et al. TMEM126A, encoding a mitochondrial protein, is mutated in autosomal-recessive nonsyndromic optic atrophy. Am. J. Hum. Genet. 84(4), 493–498 (2009).
   PubMedGoogle Scholar
• Meyer E, Michaelides M, Tee LJ et al. Nonsense mutation in TMEM126A causing autosomal recessive optic atrophy and auditory neuropathy. Mol. Vis. 16, 650–664 (2010).
   PubMedGoogle Scholar
• Barrett TG, Poulton K, Bundey S. DIDMOAD syndrome; further studies and muscle biochemistry. J. Inherit. Metab. Dis. 18(2), 218–220 (1995).
   PubMedGoogle Scholar
• Barrett TG, Bundey SE, Macleod AF. Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome. Lancet 346(8988), 1458–1463 (1995).
   PubMed Web of Science ®Google Scholar
• Eiberg H, Hansen L, Kjer B et al. Autosomal dominant optic atrophy associated with hearing impairment and impaired glucose regulation caused by a missense mutation in the WFS1 gene. J. Med. Genet. 43(5), 435–440 (2006).
   PubMed Web of Science ®Google Scholar
• Rendtorff ND, Lodahl M, Boulahbel H et al. Identification of p.A684V missense mutation in the WFS1 gene as a frequent cause of autosomal dominant optic atrophy and hearing impairment. Am. J. Med. Genet. A 155A(6), 1298–1313 (2011).
   PubMed Web of Science ®Google Scholar
• Assink JJ, Tijmes NT, ten Brink JB et al. A gene for X-linked optic atrophy is closely linked to the Xp11.4-Xp11.2 region of the X chromosome. Am. J. Hum. Genet. 61(4), 934–939 (1997).
   PubMedGoogle Scholar
• Kerrison JB, Arnould VJ, Ferraz Sallum JM et al. Genetic heterogeneity of dominant optic atrophy, Kjer type: identification of a second locus on chromosome 18q12.2–12.3. Arch. Ophthalmol. 117(6), 805–810 (1999).
   PubMedGoogle Scholar
• Barbet F, Hakiki S, Orssaud C et al. A third locus for dominant optic atrophy on chromosome 22q. J. Med. Genet. 42(1), e1 (2005).
   PubMed Web of Science ®Google Scholar
• Barbet F, Gerber S, Hakiki S et al. A first locus for isolated autosomal recessive optic atrophy (ROA1) maps to chromosome 8q. Eur. J. Hum. Genet. 11(12), 966–971 (2003).
   PubMedGoogle Scholar
• Bindoff LA, Desnuelle C, Birch-Machin MA et al. Multiple defects of the mitochondrial respiratory chain in a mitochondrial encephalopathy (MERRF): a clinical, biochemical and molecular study. J. Neurol. Sci. 102(1), 17–24 (1991).
   PubMedGoogle Scholar
• Blakely EL, Trip SA, Swalwell H et al. A new mitochondrial transfer RNAPro gene mutation associated with myoclonic epilepsy with ragged-red fibers and other neurological features. Arch. Neurol. 66(3), 399–402 (2009).
   PubMedGoogle Scholar
• Shoffner JM, Lott MT, Lezza AM, Seibel P, Ballinger SW, Wallace DC. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation. Cell 61(6), 931–937 (1990).
   PubMed Web of Science ®Google Scholar
• Voo I, Allf BE, Udar N, Silva-Garcia R, Vance J, Small KW. Hereditary motor and sensory neuropathy type VI with optic atrophy. Am. J. Ophthalmol. 136(4), 670–677 (2003).
   PubMedGoogle Scholar
• Rouzier C, Bannwarth S, Chaussenot A et al. The MFN2 gene is responsible for mitochondrial DNA instability and optic atrophy ‘plus’ phenotype. Brain 135(Pt 1), 23–34 (2012).
   PubMedGoogle Scholar
• Sitarz KS, Yu-Wai-Man P, Pyle A et al. MFN2 mutations cause compensatory mitochondrial DNA proliferation. Brain 135(Pt 8), e219.1–3; author reply e220.1 (2012).
   Google Scholar
• Rosenberg RN, Chutorian A. Familial opticoacoustic nerve degeneration and polyneuropathy. Neurology 17(9), 827–832 (1967).
   PubMedGoogle Scholar
• Becker MA, Meyer LJ, Seegmiller JE. Gout with purine overproduction due to increased phosphoribosylpyrophosphate synthetase activity. Am. J. Med. 55(2), 232–242 (1973).
   PubMedGoogle Scholar
• Becker MA, Puig JG, Mateos FA, Jimenez ML, Kim M, Simmonds HA. Inherited superactivity of phosphoribosylpyrophosphate synthetase: association of uric acid overproduction and sensorineural deafness. Am. J. Med. 85(3), 383–390 (1988).
   PubMedGoogle Scholar
• de Brouwer AP, Williams KL, Duley JA et al. Arts syndrome is caused by loss-of-function mutations in PRPS1. Am. J. Hum. Genet. 81(3), 507–518 (2007).
   PubMed Web of Science ®Google Scholar
• Arts WF, Loonen MC, Sengers RC, Slooff JL. X-linked ataxia, weakness, deafness, and loss of vision in early childhood with a fatal course. Ann. Neurol. 33(5), 535–539 (1993).
   PubMedGoogle Scholar
• Schnitzler A, Witte OW, Kunesch E, Freund HJ, Benecke R. Early-onset multisystem degeneration with central motor, autonomic and optic nerve disturbances: unusual Riley–Day syndrome or new clinical entity? J. Neurol. Sci. 154(2), 205–208 (1998).
   PubMedGoogle Scholar
• Rizzo JF 3rd, Lessell S, Liebman SD. Optic atrophy in familial dysautonomia. Am. J. Ophthalmol. 102(4), 463–467 (1986).
   PubMedGoogle Scholar
• Orr HT, Chung MY, Banfi S et al. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat. Genet. 4(3), 221–226 (1993).
   PubMed Web of Science ®Google Scholar
• Buttner N, Geschwind D, Jen JC, Perlman S, Pulst SM, Baloh RW. Oculomotor phenotypes in autosomal dominant ataxias. Arch. Neurol. 55(10), 1353–1357 (1998).
   PubMedGoogle Scholar
• Paulson H, Ammache Z. Ataxia and hereditary disorders. Neurol. Clin. 19(3), 759–782, viii (2001).
   PubMed Web of Science ®Google Scholar
• Gouw LG, Castañeda MA, McKenna CK et al. Analysis of the dynamic mutation in the SCA7 gene shows marked parental effects on CAG repeat transmission. Hum. Mol. Genet. 7(3), 525–532 (1998).
   PubMedGoogle Scholar
• Van De Warrenburg BP, Frenken CW, Ausems MG et al. Striking anticipation in spinocerebellar ataxia type 7: the infantile phenotype. J. Neurol. 248(10), 911–914 (2001).
   PubMedGoogle Scholar
• Ansorge O, Giunti P, Michalik A et al. Ataxin-7 aggregation and ubiquitination in infantile SCA7 with 180 CAG repeats. Ann. Neurol. 56(3), 448–452 (2004).
   PubMedGoogle Scholar
• Dürr A, Cossee M, Agid Y et al. Clinical and genetic abnormalities in patients with Friedreich’s ataxia. N. Engl. J. Med. 335(16), 1169–1175 (1996).
   PubMed Web of Science ®Google Scholar
• Harding AE. Friedreich’s ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 104(3), 589–620 (1981).
   PubMed Web of Science ®Google Scholar
• Bidichandani SI, Garcia CA, Patel PI, Dimachkie MM. Very late-onset Friedreich ataxia despite large GAA triplet repeat expansions. Arch. Neurol. 57(2), 246–251 (2000).
   PubMedGoogle Scholar
• Bhidayasiri R, Perlman SL, Pulst SM, Geschwind DH. Late-onset Friedreich ataxia: phenotypic analysis, magnetic resonance imaging findings, and review of the literature. Arch. Neurol. 62(12), 1865–1869 (2005).
   PubMedGoogle Scholar
• Galimanis A, Glutz L, Spiegel R, Burgunder JM, Kaelin-Lang A. Very-late-onset Friedreich ataxia with disturbing head tremor and without spinal atrophy – a case report. Mov. Disord. 23(7), 1058–1059 (2008).
   PubMedGoogle Scholar
• Fortuna F, Barboni P, Liguori R et al. Visual system involvement in patients with Friedreich’s ataxia. Brain 132(Pt 1), 116–123 (2009).
   PubMed Web of Science ®Google Scholar
• Cossée M, Dürr A, Schmitt M et al. Friedreich’s ataxia: point mutations and clinical presentation of compound heterozygotes. Ann. Neurol. 45(2), 200–206 (1999).
   PubMed Web of Science ®Google Scholar
• Porter N, Downes SM, Fratter C, Anslow P, Németh AH. Catastrophic visual loss in a patient with Friedreich ataxia. Arch. Ophthalmol. 125(2), 273–274 (2007).
   PubMedGoogle Scholar
• Camacho LM, Wenzel W, Aschoff JC. The pattern-reversal visual evoked potential in the clinical study of lesions of the optic chiasm and visual pathway. Adv. Neurol. 32, 49–59 (1982).
   PubMedGoogle Scholar
• Th BS, Chisholm AW, Mc KV. Cardiac aspects of Friedreich’s ataxia. Circulation 25, 493–505 (1962).
   PubMedGoogle Scholar
• Chamberlain S, Shaw J, Rowland A et al. Mapping of mutation causing Friedreich’s ataxia to human chromosome 9. Nature 334(6179), 248–250 (1988).
   PubMed Web of Science ®Google Scholar
• Fujita R, Agid Y, Trouillas P et al. Confirmation of linkage of Friedreich ataxia to chromosome 9 and identification of a new closely linked marker. Genomics 4(1), 110–111 (1989).
   PubMedGoogle Scholar
• Cossée M, Schmitt M, Campuzano V et al. Evolution of the Friedreich’s ataxia trinucleotide repeat expansion: founder effect and premutations. Proc. Natl Acad. Sci. USA 94(14), 7452–7457 (1997).
   PubMed Web of Science ®Google Scholar
• Montermini L, Andermann E, Labuda M et al. The Friedreich ataxia GAA triplet repeat: premutation and normal alleles. Hum. Mol. Genet. 6(8), 1261–1266 (1997).
   PubMedGoogle Scholar
• Sharma R, De Biase I, Gómez M, Delatycki MB, Ashizawa T, Bidichandani SI. Friedreich ataxia in carriers of unstable borderline GAA triplet-repeat alleles. Ann. Neurol. 56(6), 898–901 (2004).
   PubMedGoogle Scholar
• Forrest SM, Knight M, Delatycki MB et al. The correlation of clinical phenotype in Friedreich ataxia with the site of point mutations in the FRDA gene. Neurogenetics 1(4), 253–257 (1998).
   PubMed Web of Science ®Google Scholar
• Vermeer S, Van Den Warrenburg BP, Kamsteg EJ. ARSACS. In: Gene Reviews. Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP (Eds). University of Washington, WA, USA (2003).
   Google Scholar
• Percy AK, Brady RO. Metachromatic leukodystrophy: diagnosis with samples of venous blood. Science 161(3841), 594–595 (1968).
   PubMedGoogle Scholar
• Austin J, McAfee D, Armstrong D, O’Rourke M, Shearer L, Bachhawat B. Abnormal sulphatase activities in two human diseases (metachromatic leucodystrophy and gargoylism). Biochem. J. 93(2), 15C–17C (1964).
   Web of Science ®Google Scholar
• Bayever E, Ladisch S, Philippart M et al. Bone-marrow transplantation for metachromatic leucodystrophy. Lancet 2(8453), 471–473 (1985).
   PubMed Web of Science ®Google Scholar
• Krivit W, Shapiro E, Kennedy W et al. Treatment of late infantile metachromatic leukodystrophy by bone marrow transplantation. N. Engl. J. Med. 322(1), 28–32 (1990).
   PubMed Web of Science ®Google Scholar
• D’Agostino AN, Sayre GP, Hayles AB. Krabbe’s disease. Globoid cell type of leukodystrophy. Arch. Neurol. 8, 82–96 (1963).
   PubMedGoogle Scholar
• Husain AM, Altuwaijri M, Aldosari M. Krabbe disease: neurophysiologic studies and MRI correlations. Neurology 63(4), 617–620 (2004).
   PubMedGoogle Scholar
• Krivit W, Shapiro EG, Peters C et al. Hematopoietic stem-cell transplantation in globoid-cell leukodystrophy. N. Engl. J. Med. 338(16), 1119–1126 (1998).
   PubMed Web of Science ®Google Scholar
• Renier WO, Gabreëls FJ, Hustinx TW et al. Connatal Pelizaeus–Merzbacher disease with congenital stridor in two maternal cousins. Acta Neuropathol. 54(1), 11–17 (1981).
   PubMedGoogle Scholar
• Schaumburg HH, Powers JM, Raine CS, Suzuki K, Richardson EP Jr. Adrenoleukodystrophy. A clinical and pathological study of 17 cases. Arch. Neurol. 32(9), 577–591 (1975).
   PubMedGoogle Scholar
• Moser HW, Moser AB, Frayer KK et al. Adrenoleukodystrophy: increased plasma content of saturated very long chain fatty acids. Neurology 31(10), 1241–1249 (1981).
   PubMedGoogle Scholar
• Aubourg P, Chaussain JL, Dulac O, Arthuis M. Adrenoleukodystrophy in children. Apropos of 20 cases. Arch. Fr. Pediatr. 39(9), 663–669 (1982).
   PubMedGoogle Scholar
• Neufeld EF. Natural history and inherited disorders of a lysosomal enzyme, beta-hexosaminidase. J. Biol. Chem. 264(19), 10927–10930 (1989).
   PubMedGoogle Scholar
• Gregory A, Polster BJ, Hayflick SJ. Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J. Med. Genet. 46(2), 73–80 (2009).
   PubMed Web of Science ®Google Scholar
• Hartig MB, Hörtnagel K, Garavaglia B et al. Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. Ann. Neurol. 59(2), 248–256 (2006).
   PubMedGoogle Scholar
• Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden–Spatz syndrome. Nat. Genet. 28(4), 345–349 (2001).
   PubMed Web of Science ®Google Scholar
• Morgan NV, Westaway SK, Morton JE et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat. Genet. 38(7), 752–754 (2006).
   PubMed Web of Science ®Google Scholar
• Curtis AR, Fey C, Morris CM et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat. Genet. 28(4), 350–354 (2001).
   PubMed Web of Science ®Google Scholar
• Hartig MB, Iuso A, Haack T et al. Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation. Am. J. Hum. Genet. 89(4), 543–550 (2011).
   PubMed Web of Science ®Google Scholar
• Horvath R, Holinski-Feder E, Neeve VC et al. A new phenotype of brain iron accumulation with dystonia, optic atrophy, and peripheral neuropathy. Mov. Disord. 27(6), 789–793 (2012).
   PubMed Web of Science ®Google Scholar